Login / Signup

The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.

Liana K BillingsBue F Ross AgnerYuksel AltuntasRandi GrønNatalie HalladinDavid C KlonoffNikolaos TentolourisEsteban Jódar
Published in: Journal of diabetes science and technology (2020)
NCT02420262.
Keyphrases
  • type diabetes
  • glycemic control
  • stem cells
  • metabolic syndrome
  • adipose tissue
  • mesenchymal stem cells
  • skeletal muscle
  • chemotherapy induced